The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Naughty rns talking about 200m euro pontential revenue.. well FIPP only own 5% of company that is mentioned in rns.. so that's a share to them max of 10m..
The herd buy in seeing $250m, fail to do homework and realise the Co only own 5% and regardless the payment is at the end of a lengthy trials process , and also a maximum, not a minimum. Thats what has happened folks.
Hope it bounces soon
From 50 to 5% within an hour?
Happening here...should be way higher! MMs playing ?
Remember, its not FIPP , but Exscientia who have the Sanofi collaboration. FIPP hold 5% of Exscientia.
tie up with Sanofi and this guy claims P&D, LAUGHABLE.
buy quote at .459
at 44p
Back above 50p would be nice
will take 10k but unable to buy£50 quids worth.
No, false drop.
Negotiated Order Negotiated Order Your order cannot be executed automatically at this time, but can be submitted as a Negotiated Order. By accepting a Negotiated Order the price obtained is not guaranteed. By selecting the 'Place Order' option below, your order will be sent directly to our Dealers who will negotiate the best price available for your order in the market at that time. Once you have entered a Negotiated Order you do not have the facility to cancel this instruction online. Please select one of the following options: INVEST £1000 FIPP - FRONTIER IP GROUP ORD GBP0.1
At 42p
Well im in at 48.6p. Hoping sellers clear and we rocket up
58.77 will be seen very shortly
me too ... fun for the arvo.
for clarity - good trade on the news
Three Group nominations for Royal Society of Chemistry awards Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that two of its portfolio companies, Alusid Limited ("Alusid") and Exscientia Limited ("Exscientia") have received nominations for a total of three awards at the Royal Society of Chemistry's forthcoming Chemistry World flagship event in June. Alusid has been shortlisted for the Emerging Technologies competition for its multi-award winning Architectural surfacing Eco-materials, made from fused recycled glass and ceramics using a low energy process, designed as an adaptable alternative to natural stone. Alusid aims to be a leader in the supply of premium engineered sustainable architectural materials and remains at the forefront of this growing sector through continuous research and development. Exscientia is at the forefront of small molecule drug discovery. It applies a wealth of AI techniques to automate drug design in a manner that surpasses conventional human endeavour. In just three years Exscientia has already grown a portfolio of global collaborations that include Sanofi, Sumitomo Dainippon and Sunovion. Exscientia sees two of its staff shortlisted to the final three, Andrew Hopkins, as Chemistry World Entrepreneur of the Year and Jérémy Besnard for the Rising Star in Industry Award. Neil Crabb, CEO of Frontier IP, commented "It is pleasing to see both companies continuing to garner recognition for the excellence of their technologies and people as they drive commercial success in their respective marketplaces".
is powerful 10k @39.55 easy 100% from here.. NT on buyside as you would expect.
company, game changer
Just bought a few more...follow the money !
Bought a few chart is very bullish
Should note that FIpp hold only 5% of Esscientia From FIPP website EXSCIENTIA LIMITED As at 31 December 2015 – Frontier IP Group holding – 5% Sector – Life Sciences
No brainer easy money